Beyond the Triad: Uncommon Initial Presentations in Newly Diagnosed Type 2 Diabetes Mellitus
- PMID: 40787191
- PMCID: PMC12332044
- DOI: 10.7759/cureus.89525
Beyond the Triad: Uncommon Initial Presentations in Newly Diagnosed Type 2 Diabetes Mellitus
Abstract
Background Type 2 diabetes mellitus (T2DM) often presents with a range of symptoms, many of which are under-recognized, leading to delayed diagnosis. Objective To analyze the range of initial presenting symptoms in newly diagnosed patients with T2DM in an outpatient setting. Methods A retrospective study of 50 newly diagnosed patients with T2DM aged 30-65 years was conducted at Aster DM Healthcare, Dubai. Their presenting symptoms and laboratory results were recorded. Symptoms were categorized as classical (polyuria, polydipsia, fatigue, and weight loss) and atypical (blurred vision, pruritus, skin infections, and delayed wound healing). Laboratory parameters such as fasting blood sugar (FBS), random blood sugar (RBS), glycated hemoglobin (HbA1c) and urine routine were analyzed. Results Classic presenting symptoms were polyuria (n=30; 60%), polydipsia (n=28; 56%), fatigue (n=25; 50%), and weight loss (n=19;38%). Atypical initial presenting symptoms included blurred vision (n=13; 26%), pruritus (n=10; 20%), recurrent vaginal infections (n=6; 24% of females), and delayed wound healing (n=8; 16%). Obese patients were significantly more likely to present with atypical symptoms. Females were more likely to report fatigue, pruritus, and candidiasis. Conclusion This case series of 50 newly diagnosed patients with T2DM reveals a high prevalence of atypical symptoms, especially in women and in those with obesity. Fatigue, pruritus, and visual disturbances were common non-classical features. These findings support expanding screening criteria to include atypical presentations, promoting earlier diagnosis and intervention, particularly in high-risk populations.
Keywords: atypical symptoms; diabetes; fatigue; newly diagnosed type 2 diabetes; polydipsia; polyuria; presenting symptoms; weight loss.
Copyright © 2025, Joseph et al.
Conflict of interest statement
Human subjects: Informed consent for treatment and open access publication was obtained or waived by all participants in this study. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.
Similar articles
-
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3. Cochrane Database Syst Rev. 2022. PMID: 35593186 Free PMC article.
-
Pediatric Diabetic Ketoacidosis (PDKA) among newly diagnosed diabetic patients at Dilla University Hospital, Dilla, Ethiopia: Prevalence and predictors.PLoS One. 2025 Jan 30;20(1):e0314433. doi: 10.1371/journal.pone.0314433. eCollection 2025. PLoS One. 2025. PMID: 39883619 Free PMC article.
-
Glycaemic and Weight Control in People Aged 65 or Younger Newly Diagnosed with Type 2 Diabetes in Spain: Insights from the PRIORITY-T2D Study.Adv Ther. 2025 Jul;42(7):3354-3368. doi: 10.1007/s12325-025-03230-7. Epub 2025 May 19. Adv Ther. 2025. PMID: 40388088 Free PMC article.
-
Preexisting Diabetes and Pregnancy: An Endocrine Society and European Society of Endocrinology Joint Clinical Practice Guideline.Eur J Endocrinol. 2025 Jun 30;193(1):G1-G48. doi: 10.1093/ejendo/lvaf116. Eur J Endocrinol. 2025. PMID: 40652450
-
Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.Cochrane Database Syst Rev. 2017 May 10;5(5):CD012204. doi: 10.1002/14651858.CD012204.pub2. Cochrane Database Syst Rev. 2017. PMID: 28489279 Free PMC article.
References
-
- Magliano DJ, Boyko EJ. IDF Diabetes Atlas, 10th edition. Brussels: International Diabetes Federation; 2021. IDF Diabetes Atlasscientific committee. IDF Diabetes Atlas.
-
- Current status of screening for diabetic retinopathy in the UK. Younis N, Broadbent DM, James M, Harding SP, Vora JP. Diabet Med. 2002;19:44–49. - PubMed
-
- Pakistan national diabetes survey: prevalence of glucose intolerance and associated factors in Baluchistan province. Shera AS, Rafique G, Khwaja IA, Baqai S, King H. Diab Res Clin Prac. 1999;44:49–58. - PubMed
LinkOut - more resources
Full Text Sources